Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biogen Inc. (BIIB) is currently conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL). The study aims to evaluate the effects of felzartamab on proteinuria in patients with Immunoglobulin A Nephropathy (IgAN), a kidney condition that leads to protein in urine due to kidney damage.
The study tests the drug felzartamab, administered via intravenous infusions, against a placebo. Felzartamab is intended to reduce proteinuria and improve kidney function in IgAN patients.
This interventional study is randomized with a parallel assignment model and uses quadruple masking to ensure unbiased results. Its primary purpose is treatment-focused, aiming to assess the drug’s efficacy and safety.
The study began on May 8, 2025, with an estimated completion timeline not yet disclosed. The last update was submitted on August 19, 2025, indicating ongoing recruitment and progress.
The outcome of this study could significantly impact Biogen’s stock performance, as successful results may enhance investor confidence and position Biogen favorably against competitors in the nephrology market.
The study is ongoing, with further details available on the ClinicalTrials portal.